According to a statement by the pharma company, Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators including the US Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors, respectively.
Mumbai (Maharashtra)/ New Delhi [India], October 10 (ANI/BusinessWire India): Cyril Amarchand Mangaldas advised Biocon Limited (Biocon), in relation to the sale of shares by Biocon Limited in Syngene International Limited (Syngene International), by way of a bulk trade on the stock exchanges, aggregating to Rs 1220.28 crores.
\
\
\
\
